Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Gastroenterology

• Publication date

  2010-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.gastro.2010.01.042PMID 20114048
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long‐term outcome of hepatitis B e antigen–negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time

  2009cited by this paper
• Risk and predictors of mortality associated with chronic hepatitis B infection.

  2007cited by this paper
• Spontaneous relapse of hepatitis in inactive HBsAg carriers

  2007cited by this paper
• Long-term outcomes in hepatitis B: the REVEAL-HBV study.

  2007cited by this paper
• Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B.

  2007cited by this paper
• Long term follow-up of a large cohort of inactive HBsAg (+)/ HBeAg (-)/ anti-HBe (+) carriers in Greece.

  2007cited by this paper
• Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.

  2006cited by this paper
• Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

  2006cited by this paper
• Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications

  2005cited by this paper
• Natural history of chronic HBV infection: A cohort study with up to 12 years follow‐up in North Greece (part of the Interreg I‐II/EC‐project)

  2005cited by this paper
• Liver function tests: defining what's normal

  2004cited by this paper
• Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels.

  2004cited by this paper
• Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study

  2004cited by this paper
• Molecular diagnosis of viral hepatitis.

  2002cited by this paper
• Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers.

  2002cited by this paper
• Hepatitis B e antigen and the risk of hepatocellular carcinoma.

  2002cited by this paper
• Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels

  2002cited by this paper
• Alanine Aminotransferase Levels: What's Normal?

  2002cited by this paper
• Management of hepatitis B: 2000--summary of a workshop.

  2001cited by this paper
• Hepatitis B e antigen–negative chronic hepatitis B

  2001cited by this paper
• [Chronic hepatitis B].

  2001cited by this paper
• Chronic hepatitis B

  2001cited by this paper
• Hepatitis B virus infection.

  1997cited by this paper
• Small sample and efficiency results for the Nelson-Aalen estimator

  1993cited by this paper
• Nonparametric Inference for a Family of Counting Processes

  1978cited by this paper
• A Large Sample Study of the Life Table and Product Limit Estimates Under Random Censorship

  1974cited by this paper
• Transaminase activity in human blood.

  1955cited by this paper

• Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg‐Negative Patients With Normal Alanine Aminotransferase: A 48‐Week Randomised Controlled Trial

  2026cites this paper
• Functional Cure for Hepatitis B Virus: Challenges and Achievements

  2025cites this paper
• EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection

  2025cites this paper
• Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon

  2025cites this paper
• Short-term pegylated interferon alpha in chronic HBV patients with ultra-low HBsAg: a retrospective study

  2025cites this paper
• Surface Gene Mutations of Hepatitis B Virus and Related Pathogenic Mechanisms: A Narrative Review

  2025cites this paper
• Management of inactive HBsAg carriers: an analysis based on current clinical evidence

  2025cites this paper
• HBV induces liver fibrosis through the generation of reactive oxygen species in a pyruvate-dependent manner.

  2025cites this paper
• Factors Associated with Progressive Liver Disease in Untreated HBV Patients in Tunisia

  2025cites this paper
• Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL‐B Study

  2025cites this paper
• Clinical Impact of Continuation Versus Cessation of Antiviral Therapy in Chronic Hepatitis B: A Modelling Study With Implications for Hepatitis B Cure

  2025cites this paper
• Ten-Year Trends in Hepatocellular Carcinoma Mortality: Examining the Interaction Between Fibrosis Score and Patient Age

  2025cites this paper
• Factors associated with progression of fibrosis in chronic hepatitis B virus infection in the indeterminate phase

  2025cites this paper
• EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.

  2025cites this paper
• Hepatitis B surface antigen level identifies patients with inactive chronic hepatitis B from Asia with HCC risk below surveillance threshold

  2025cites this paper
• Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study

  2024cites this paper
• HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx

  2024cites this paper
• Interaction Between Hepatitis B, Hepatitis C and Alcohol in the Development of Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis

  2024cites this paper
• Chronic Hepatitis B in Which HBs Antigen Seroclearance Was Induced by Pegpegylated-interferonα-2a after Hepatocellular Carcinoma Treatment with Nucleos(t)ide Analogues: A Five-year Follow-up

  2024cites this paper
• Stat3 activation-triggered transcriptional networks govern the early stage of HBV-induced hepatic inflammation

  2024cites this paper
• Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA

  2024influential citation
• Novel biomarkers for chronic hepatitis B management.

  2024cites this paper
• Diagnostic Significance of Serum Long Noncoding HOX Antisense Intergenic Ribonucleic Acid in Patients with Hepatitis B Virus Related Hepatocellular Carcinoma

  2024cites this paper
• Should Indications for Antiviral Therapy for Hepatitis B Be Broadened to Include Immune-Tolerant Patients, Inactive Carriers, or Patients in the “Gray Zone”?

  2024cites this paper
• Diagnostic precision of Truenat® technique and co-relation of ALT levels with HBV-DNA viral load among HBsAg positive patients at a tertiary care hospital in Eastern Uttar Pradesh

  2024cites this paper
• The surety or otherwise of leaving chronic hepatitis B untreated.

  2024cites this paper
• Clinical outcomes of untreated adults living with chronic hepatitis B in The Gambia: an analysis of data from the prospective PROLIFICA cohort study.

  2024cites this paper
• Precision Management of Patients with HBV Infection

  2024cites this paper
• HBV‐Induced Carcinogenesis: Mechanisms, Correlation With Viral Suppression, and Implications for Treatment

  2024cites this paper
• Factors influencing pathological changes in the liver tissue in hepatitis B virus carriers with low-level viremia.

  2024cites this paper
• Assessment of Viral and Clinical Characteristics Among Patients With Chronic Hepatitis B Virus Infection in Georgia.

  2023cites this paper
• Clinical characteristics and risk factors of hepatitis B virus-related cirrhosis/hepatocellular carcinoma: A single-center retrospective study

  2023cites this paper
• Alcool et virus

  2023cites this paper
• Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection

  2023cites this paper
• Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication

  2023cites this paper
• Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B

  2023cites this paper
• Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma

  2023cites this paper
• Survival Outcome and Prognostic Factors Among Patients With Hepatocellular Carcinoma: A Hospital-Based Study

  2023cites this paper
• Triple motif proteins 19 and 38 correlated with treatment responses and HBsAg clearance in HBeAg-negative chronic hepatitis B patients during peg-IFN-α therapy

  2023cites this paper
• Effective Analysis of Antiviral Treatment in Patients with HBeAg-Seropositive Chronic Hepatitis B with ALT < 2 Upper Limits of Normal: A Multi-center Retrospective Cohort Study

  2023cites this paper
• Lifetime risk of liver‐related outcomes and determinants in male inactive carriers of chronic hepatitis B

  2023influential citation
• Hepatitis B virus associated cirrhosis: overview of prognostic and management

  2023cites this paper
• The incidence of liver abnormalities is higher in inactive hepatitis B virus carriers with influenza A infection

  2023cites this paper
• The efficacy and safety of pegylated interferon α-2b-based immunotherapy for inactive hepatitis B surface antigen carriers

  2023cites this paper
• A Literature Review on the Antiviral Mechanism of Luteolin

  2023cites this paper
• Novel insights into HBV‐hepatocellular carcinoma at single‐cell sequencing

  2023cites this paper
• A Personal Growth System Supporting the Sustainable Development of Students Based on Intelligent Graph Element Technology

  2022cites this paper
• Costs and health impact of delayed implementation of a national hepatitis B treatment program in China

  2022cites this paper
• Development and Validation of a Non-invasive Model to Predict Liver Histological Lesions in Chronic Hepatitis B Patients With Persistently Normal Alanine Aminotransferase and Detectable Viremia

  2022cites this paper
• Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment

  2022cites this paper
• PD-L1 Silencing in Liver Using siRNAs Enhances Efficacy of Therapeutic Vaccination for Chronic Hepatitis B

  2022cites this paper
• Perspectives on current controversial issues in the management of chronic HBV infection

  2022cites this paper
• H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection

  2022cites this paper
• Risk Associations of Glycemic Burden and Obesity With Liver Cancer—A 10‐Year Analysis of 15,280 Patients With Type 2 Diabetes

  2022cites this paper
• Expanding antiviral therapy indications for HBeAg-negative chronic hepatitis B patients with normal ALT and positive HBV DNA

  2022cites this paper
• Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon

  2022cites this paper
• Community-Based Screening for Hepatitis B and C Infectivity Using Two Quantitative Antigens to Identify Endemic Townships

  2022cites this paper
• Current Best Practice in Hepatitis B Management & Understanding Long-Term Prospects for Cure.

  2022cites this paper
• African Immigrants in New York City with Hepatitis B-Related Hepatocellular Carcinoma Demonstrate High Morbidity and Mortality

  2021cites this paper
• Chronic Viral Hepatitis B and C

  2021cites this paper
• Liver Cancer (Current Therapies)

  2021cites this paper
• Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers

  2021cites this paper
• Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study

  2021cites this paper
• High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B

  2021influential citation
• Chronic hepatitis B: the demise of the ‘inactive carrier’ phase

  2021cites this paper
• Effect of pegylated interferon alfa-2a in HBeAg-negative chronic hepatitis B during and 48 weeks after off-treatment follow-up: the limitation of pre-treatment HBsAg load for the seroclearance of HBsAg

  2021cites this paper
• Peginterferon alfa-2b Combined with Tenofovir Disoproxil Fumarate Induced High Clinical Cure Rate in Inactive Chronic Hepatitis B Virus Carriers.

  2021cites this paper
• Multicenter Evaluation of the Cepheid Xpert® HBV Viral Load Test

  2021cites this paper
• Dual Agonist of Farnesoid X Receptor and Takeda G Protein‐Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo

  2021cites this paper
• Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis

  2021cites this paper
• Advances in Multi-Omics Applications in HBV-Associated Hepatocellular Carcinoma

  2021cites this paper
• Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B

  2021cites this paper
• Epidemiology and Natural History of Hepatitis B Virus Infection: Time-Dependent Driving Factors of Chronic Hepatitis B Progression

  2021cites this paper
• The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals

  2021cites this paper
• Analysis of the Efficacy and Safety of PEGylated Interferon-α2b Treatment in Inactive Hepatitis B Surface Antigen Carriers

  2021cites this paper
• Tenofovir alafenamide fumarate therapy in subjects with positive HBV-DNA and normal levels of alanine transaminase: a study protocol for a randomised controlled trial

  2021cites this paper
• Antiviral Therapy for Chronic HBV Infection With Persistently Normal Alanine Aminotransferase: Controversy and Consensus

  2021influential citation
• Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection

  2021cites this paper
• Longitudinal changes in physical and mental health of older adults with chronic hepatitis B infection: Trajectories and predictors

  2021cites this paper
• HBsAg Dampened STING Associated Activation of NK Cells in HBeAg-Negative CHB Patients

  2021cites this paper
• S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11)

  2021cites this paper
• Predictive factors for risk of hepatocellular carcinoma in immune inactive chronic hepatitis B.

  2020cites this paper
• Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve.

  2020cites this paper
• Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-titer HBV Carrier Mice.

  2020cites this paper
• Infectious Conditions and the Immune System in Elders

  2020cites this paper
• Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy.

  2020cites this paper
• Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy

  2020cites this paper
• Liver Cancer

  2020cites this paper
• Contemporary Techniques and Applications of Radioembolization in Patients with Hepatocellular Carcinoma

  2020cites this paper
• Novel biomarkers for the management of chronic hepatitis B

  2020cites this paper
• Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma.

  2020cites this paper
• Antitumor effects of triterpenes in hepatocellular carcinoma.

  2020cites this paper
• Hepatitis B virus‐related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non‐viral risk factors

  2020cites this paper
• Should treatment indications for chronic hepatitis B be expanded?

  2020cites this paper
• The Quantum microRNA Immunity in Human Virus-Associated Diseases: Virtual Reality of HBV, HCV and HIV-1 Infection, and Hepatocellular Carcinogenesis with AI Machine Learning

  2020cites this paper
• Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus

  2020cites this paper
• Presence of Hepatic Steatosis Does Not Increase the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Over Long Follow-Up

  2020cites this paper
• Expanding Antiviral Prophylaxis During Pregnancy to Prevent Perinatal Hepatitis B Virus Infection: A Cost-effectiveness Study

  2020cites this paper
• Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management.

  2020cites this paper
• Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B‐related hepatocellular carcinoma

  2020cites this paper